View : 271 Download: 88

Full metadata record

DC Field Value Language
dc.contributor.author김민혜*
dc.contributor.author심지수*
dc.date.accessioned2023-01-06T16:31:07Z-
dc.date.available2023-01-06T16:31:07Z-
dc.date.issued2022*
dc.identifier.issn1939-4551*
dc.identifier.otherOAK-32742*
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/263117-
dc.description.abstract338489296_20221221170722203 responders; 2) doctor-diagnosed asthma-chronic obstructive pulmonary disease overlap (ACO) [OR = 12.6, 95% CI: 1.8-161.5, P = 0.024], and 3) initial ACT score <20 [OR = 24.1, 95% CI: 5.45- 158.8, P < 0.001] for ACT responders. FEV1 responders also showed a longer exacerbation-free period than those with no FEV1 increase (P = 0.014), yielding a hazard ratio for the first asthma exacerbation of 0.5 (95% CI: 0.3-0.9, P = 0.016). Conclusions: The results of this study suggest that tiotropium add-on for uncontrolled asthma with ICS-LABA would be more effective in patients with positive BDR or ACO. Additionally, an increase in FEV1 following tiotropium may predict a lower risk of asthma exacerbation.*
dc.languageEnglish*
dc.publisherELSEVIER*
dc.subjectTiotropium*
dc.subjectMuscarinic antagonists*
dc.subjectAsthma*
dc.subjectTreatment response*
dc.subjectPredictor*
dc.titleClinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea*
dc.typeArticle*
dc.relation.issue12*
dc.relation.volume15*
dc.relation.indexSCIE*
dc.relation.indexSCOPUS*
dc.relation.journaltitleWORLD ALLERGY ORGANIZATION JOURNAL*
dc.identifier.doi10.1016/j.waojou.2022.100720*
dc.identifier.wosidWOS:000904490300009*
dc.identifier.scopusid2-s2.0-85142432560*
dc.author.googleShim, Ji-Su*
dc.author.googleJin, Juhae*
dc.author.googleKim, Sae-Hoon*
dc.author.googleLee, Taehoon*
dc.author.googleJang, An-Soo*
dc.author.googlePark, Chan Sun*
dc.author.googleJung, Jae-Woo*
dc.author.googleKwon, Jae-Woo*
dc.author.googleMoon, Ji-Yong*
dc.author.googleYang, Min-Suk*
dc.author.googleLee, Jaechun*
dc.author.googleChoi, Jeong-Hee*
dc.author.googleShin, Yoo Seob*
dc.author.googleKim, Hee-Kyoo*
dc.author.googleKim, Sujeong*
dc.author.googleKim, Joo-Hee*
dc.author.googleCho, Sang-Heon*
dc.author.googleNam, Young-Hee*
dc.author.googleKim, Sang-Hoon*
dc.author.googlePark, So Young*
dc.author.googleHur, Gyu Young*
dc.author.googleKim, Sang-Ha*
dc.author.googlePark, Hye-Kyung*
dc.author.googleJin, Hyun Jung*
dc.author.googleLee, Jae-Hyun*
dc.author.googlePark, Jung-Won*
dc.author.googleYoon, Ho Joo*
dc.author.googleChoi, Byoung Whui*
dc.author.googleCho, Young-Joo*
dc.author.googleKim, Min-Hye*
dc.author.googleKim, Tae-Bum|Cohort Reality Evolution Adult Ast*
dc.contributor.scopusid김민혜(58045929900)*
dc.contributor.scopusid심지수(57193221759)*
dc.date.modifydate20240315131743*


qrcode

BROWSE